Egetis Therapeutics AB (publ) (STO:EGTX)
Sweden · Delayed Price · Currency is SEK | Market Cap | 3.02B +126.6% |
| Revenue (ttm) | 63.10M +35.1% |
| Net Income | -374.10M |
| EPS | -0.99 |
| Shares Out | 461.83M |
| PE Ratio | n/a |
| Forward PE | 22.15 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 934,320 |
| Average Volume | 935,822 |
| Open | 6.67 |
| Previous Close | 6.67 |
| Day's Range | 6.46 - 6.75 |
| 52-Week Range | 3.03 - 7.07 |
| Beta | 0.76 |
| RSI | 59.57 |
| Earnings Date | Apr 29, 2026 |
About Egetis Therapeutics AB
Egetis Therapeutics AB (publ), a pharmaceutical company, engages in the development and commercialization of orphan drugs in Sweden and internationally. It develops Aladote, which is in Phase IIb/III clinical trial for the treatment of paracetamol/acetaminophen overdosing and for the prevention of acute liver failure in paracetamol poisoning; and Emcitate, which is in Phase IIb clinical trial for the treatment of monocarboxylate transporter 8 deficiency. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Thera... [Read more]
Financial Performance
In 2025, Egetis Therapeutics AB's revenue was 62.40 million, an increase of 35.36% compared to the previous year's 46.10 million. Losses were -342.50 million, -0.32% less than in 2024.
Financial StatementsNews
Egetis Therapeutics AB Earnings Call Transcript: Q1 2026
FDA accepted NDA for Emcitate with priority review and a Q4 2026 U.S. launch expected. Q1 revenue grew 9% year-over-year, and SEK 350 million was raised to support commercialization and pipeline expansion. European sales momentum continues despite reimbursement challenges.
Egetis Therapeutics AB Quarterly report: Q1 2026
Egetis Therapeutics AB has published its Q1 2026 quarterly earnings report on April 29, 2026.
Egetis Therapeutics AB Earnings Call Transcript: Q1 2026
FDA accepted NDA for Emcitate with priority review and a Q4 2026 U.S. launch expected. Q1 revenue grew 9% year-over-year, and SEK 350 million was raised to support commercialization and pipeline expansion. European sales momentum continues despite reimbursement challenges.
Egetis Therapeutics AB Quarterly report: Q1 2026
Egetis Therapeutics AB has published its Q1 2026 quarterly earnings report on April 29, 2026.
Egetis Therapeutics AB Slides: Corporate presentation
Egetis Therapeutics AB has posted slides in relation to its latest quarterly earnings report, which was published on April 7, 2026.
Egetis Therapeutics AB Slides: Corporate presentation
Egetis Therapeutics AB has posted slides in relation to its latest quarterly earnings report, which was published on April 7, 2026.
Egetis Therapeutics AB Slides: Corporate presentation
Egetis Therapeutics AB has posted slides in relation to its latest quarterly earnings report, which was published on March 16, 2026.
Egetis Therapeutics AB Slides: Corporate presentation
Egetis Therapeutics AB has posted slides in relation to its latest quarterly earnings report, which was published on March 16, 2026.
Egetis Therapeutics AB Transcript: Leerink Global Healthcare Conference 2026
Emcitate achieved EU approval and is under FDA review, with a broad clinical dataset supporting its use in MCT8 deficiency. US launch preparations include expanded infrastructure and pricing analogs suggest a ~$1M annual price. Indication expansion and new IP strengthen the rare disease pipeline.
Egetis Therapeutics AB Transcript: Leerink Global Healthcare Conference 2026
Emcitate achieved EU approval and is under FDA review, supported by robust mortality and clinical data. U.S. commercialization efforts are ramping up, with significant patient identification and a potential $1M annual price point. Indication expansion and new IP strategies are underway.
Egetis Therapeutics AB Slides: Corporate presentation
Egetis Therapeutics AB has posted slides in relation to its latest quarterly earnings report, which was published on March 4, 2026.
Egetis Therapeutics AB Slides: Corporate presentation
Egetis Therapeutics AB has posted slides in relation to its latest quarterly earnings report, which was published on March 4, 2026.
Egetis Therapeutics AB Transcript: Fireside chat
The CEO shared insights on rare disease drug development, highlighting progress in diagnosis, regulatory milestones, and commercialization strategies. Emcitate's approval in Europe and pending U.S. launch mark significant achievements, with further pipeline expansion and profitability expected within a year of U.S. entry.
Egetis Therapeutics AB Transcript: Fireside chat
The CEO shared insights on rare disease drug development, highlighting progress in diagnosis, regulatory milestones, and commercialization strategies. Emcitate's approval in Europe and pending U.S. launch mark significant achievements, with further pipeline expansion and profitability expected within a year of U.S. entry.
Egetis Therapeutics AB Earnings Call Transcript: Q4 2025
Emcitate revenue grew 40% year-over-year to SEK 62.4 million, driven by EU launch and expanded access. U.S. NDA submission completed, with FDA decision expected in September 2026 and launch preparations underway. Patient identification in the U.S. surpassed 140, with further growth anticipated.
Egetis Therapeutics AB Annual report: Q4 2025
Egetis Therapeutics AB has published its Q4 2025 annual report on February 26, 2026.
Egetis Therapeutics AB Quarterly report: Q4 2025
Egetis Therapeutics AB has published its Q4 2025 quarterly earnings report on February 26, 2026.
Egetis Therapeutics AB Slides: Q4 2025
Egetis Therapeutics AB has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 26, 2026.
Egetis Therapeutics AB Earnings Call Transcript: Q4 2025
Emcitate revenue grew 40% year-over-year to SEK 62.4 million, driven by EU launch and expanded access. U.S. NDA submission completed, with FDA decision expected in September 2026 and launch preparations underway. Patient identification in the U.S. surpassed 140, with further growth anticipated.
Egetis Therapeutics AB Annual report: Q4 2025
Egetis Therapeutics AB has published its Q4 2025 annual report on February 26, 2026.
Egetis Therapeutics AB Quarterly report: Q4 2025
Egetis Therapeutics AB has published its Q4 2025 quarterly earnings report on February 26, 2026.
Egetis Therapeutics AB Slides: Q4 2025
Egetis Therapeutics AB has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 26, 2026.
Egetis Therapeutics AB Slides: Corporate Presentation
Egetis Therapeutics AB has posted slides in relation to its latest quarterly earnings report, which was published on December 2, 2025.
Egetis Therapeutics AB Slides: Corporate Presentation
Egetis Therapeutics AB has posted slides in relation to its latest quarterly earnings report, which was published on December 2, 2025.
Egetis Therapeutics AB Earnings Call Transcript: Q3 2025
FDA Breakthrough Therapy designation and positive ReTRIEVE study results support Triac's NDA submission for MCT8 deficiency, with U.S. launch preparations underway. Revenue and cash position improved year-over-year, bolstered by a SEK 172 million rights issue.